Back to blog

Strong Results, Weak Market Reaction – What’s Happening with Nvidia?

One of the most popular companies on Wall Street, Nvidia, released its earnings on Wednesday, February 26, 2025, confirming impressive growth in the AI chip segment. Despite this, its stock faced pressure due to expectations of a decline in gross margin, which created uncertainty among investors. However, the positive news is that Nvidia has secured enough manufacturing capacity for this year with its main supplier, TSMC. Yet, it faces the risk of new tariffs imposed by the US government.

Strong Results, Weak Market Reaction – What’s Happening with Nvidia?

Breaks Records Again, But High Gross Margins Raise Concerns

In the last quarter of fiscal year 2025 (the three-month period ending January 26, 2025), Nvidia reported the revenue of $39.3 billion, a year-on-year increase of 77.9%. Net income reached $22.1 billion, and net profit margin rose to 56%, meaning the company still keeps most of its revenues. The main revenue driver for the last three months was the data centre segment, primarily the Blackwell architecture. Despite strong results, the company’s stock dropped* as the outlook for lower gross margins caused uncertainty. The estimated value for the current quarter is 70.6%, down from 75% in the same period last year.

Graf Nvidia

Source: Investing.com*

Decline in Gaming Segment and Increasing Competition

Nvidia’s gaming segment revenues dropped to $2.5 billion in Q4, a 22% decline compared to the previous quarter. This segment mainly includes graphics cards, with the new RTX 50 series recently launched. The decline may be linked to the cyclical nature of this market, as well as increasing competition. AMD and Intel are expanding their graphics card portfolios, with AMD focusing on a better price/performance ratio and Intel gaining market share in the mainstream GPU segment. Additionally, the rising presence of China’s Huawei in the chip industry could pose a longer-term challenge, as Nvidia faces export restrictions in Asian country.

Chip Production is Secured for This Year

According to Taiwanese media, Nvidia has already secured more than 70% of the production capacity from its main supplier, TSMC, for this year. This move is in response to the growing demand for the aforementioned Blackwell chips. As the world's largest contract chipmaker, TSMC is playing a key role in the technology shift. It is the only company that provides advanced chip packaging processes en masse, which also predisposes it to strong growth. Securing advanced chip packaging for Nvidia is a clear indicator for investors that companies in this field will continue to have a strong position in the global market. TSMC’s results for the last quarter, showing significant growth, confirm that the company is preparing for another wave of demand and expanding its capacity. The year 2025 will thus be crucial for technology giants.

Market Uncertainty in the US Continues

Nvidia’s stock decline is also tied to the overall bearish trend in US markets, which are shaken by uncertainty related to the imposition of tariffs on imports to the US. Trump confirmed a 25% tariff on goods from Canada, Mexico, and an additional 10% on China. This could have a significant impact on semiconductors, as the country remains dependent on imports, particularly from Taiwan. This is unlikely to change in the near future, despite the CHIPS and Science Act, an initiative by the US government aimed at bringing the majority of advanced chip production back to the US.

The release of unemployment claims data on Thursday, which exceeded consensus estimates, also negatively impacted the markets, indicating potential weakness in the labour market.

Conclusion

Nvidia maintains a strong position and dominance in the AI sector but may face slower growth in the coming quarters. Over the past two years, it has been a major driver of Wall Street, and investors hope it will maintain this pace. The uncertainty over the past weeks was caused by the release of the Chinese app DeepSeek, which is said to contain revolutionary language models without the need for expensive advanced hardware. This brings the potential for lower AI development costs, which could hurt companies profiting from this technology. Challenges also come from changes in US trade policy, which could disrupt supply chains, still highly concentrated in the semiconductor industry.

 

* Historical data is not a guarantee of future returns.

Warning! This marketing material is not and should not be construed as investment advice. Historical data is not a guarantee of future returns. Investing in foreign currencies may affect returns due to fluctuations. All securities transactions may result in both profits and losses. Forward-looking statements represent assumptions and current expectations that may not be accurate or are based on the current economic environment, which may change. These statements do not guarantee future performance. InvestingFox is a trademark of CAPITAL MARKETS, o.c.p., a.s. regulated by the National Bank of Slovakia.

 

Sources:

https://nvidianews.nvidia.com/news/nvidia-announces-financial-results-for-fourth-quarter-and-fiscal-2025

https://www.cnbc.com/2025/02/27/nvidia-warns-of-competition-from-china-huawei-despite-us-sanctions.html

https://www.investing.com/news/stock-market-news/nvidia-secures-70-of-tsmc-advanced-packaging-capacity-for-2025-taiwan-media-3885209

https://www.congress.gov/bill/117th-congress/house-bill/4346

https://www.investing.com/news/stock-market-news/us-stock-futures-point-higher-amid-nvidia-earnings-trump-tariff-remarks-3895652

https://tradingeconomics.com/calendar

https://www.investing.com/news/stock-market-news/nvidia-q4-results-top-estimates-3894086

 

Read more

Eli Lilly Lowers the Price of Its Weight Loss Drug: More Affordable Treatment or Strategic Business Move?

Eli Lilly Lowers the Price of Its Weight Loss Drug: More Affordable Treatment or Strategic Business Move?

Pharmaceutical giant Eli Lilly has made a significant shift in its pricing strategy for the popular weight-loss drug Zepbound. The company announced that selected doses would be available at a lower price to help patients without adequate health insurance while strengthening its market position. This move comes at a time when regulatory authorities have declared the end of the drug shortage, and Eli Lilly faces growing competition. Additionally, the company is investing heavily in developing an oral alternative, which could significantly reshape the market. 

Mercedes-Benz: New Strategies on the Road to Reviving the European Market

Mercedes-Benz: New Strategies on the Road to Reviving the European Market

Recent financial results from Mercedes-Benz reveal that the company faced a harsh wake-up call last year, as it struggled with the slowing shift to electric vehicles and weakening demand in China, once an inexhaustible source of profits for German automakers. Its challenges reflect the tough period during which European vehicle manufacturers are grappling with sharp declines in sales, especially in the electric vehicle sector. However, early sales data for this year suggests improvement, which could be the first sign of market recovery.

CVS Health closed 2024 with strong results and ambitious growth plans

CVS Health closed 2024 with strong results and ambitious growth plans

CVS Health, one of the largest healthcare companies in the U.S., surprised investors with positive results for the fourth quarter of 2024. Despite challenges, it managed to exceed expectations and demonstrated stable growth in key segments. The company also presented ambitious plans for 2025, which include cost reduction and strategic improvements in Medicare Advantage insurance.

Coca-Cola Shows Resilience Against Macroeconomic Challenges

Coca-Cola Shows Resilience Against Macroeconomic Challenges

The Coca-Cola Company, a global leader in non-alcoholic beverages, known especially for its Coca-Cola brand, has reported its fourth-quarter financial results for 2024. These results not only surpassed Wall Street expectations but also confirmed steady demand growth for the company’s products despite challenging macroeconomic conditions.